JP2020513036A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020513036A5 JP2020513036A5 JP2020504094A JP2020504094A JP2020513036A5 JP 2020513036 A5 JP2020513036 A5 JP 2020513036A5 JP 2020504094 A JP2020504094 A JP 2020504094A JP 2020504094 A JP2020504094 A JP 2020504094A JP 2020513036 A5 JP2020513036 A5 JP 2020513036A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- compound
- substituted
- alkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 61
- 102000004169 proteins and genes Human genes 0.000 claims 56
- 108090000623 proteins and genes Proteins 0.000 claims 56
- 150000003839 salts Chemical class 0.000 claims 38
- 125000003118 aryl group Chemical group 0.000 claims 30
- 125000001072 heteroaryl group Chemical group 0.000 claims 24
- 125000006693 (C2-C9) heterocyclyl group Chemical group 0.000 claims 22
- 125000004452 carbocyclyl group Chemical group 0.000 claims 21
- 238000000034 method Methods 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 7
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- -1 substituted Chemical class 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 102000009658 Peptidylprolyl Isomerase Human genes 0.000 claims 5
- 108010020062 Peptidylprolyl Isomerase Proteins 0.000 claims 5
- 230000015572 biosynthetic process Effects 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 150000002678 macrocyclic compounds Chemical class 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 150000003573 thiols Chemical class 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000006413 ring segment Chemical group 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- 241000187747 Streptomyces Species 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000000855 fermentation Methods 0.000 claims 2
- 230000004151 fermentation Effects 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 102000004631 Calcineurin Human genes 0.000 claims 1
- 108010042955 Calcineurin Proteins 0.000 claims 1
- 108010077544 Chromatin Proteins 0.000 claims 1
- 102000001493 Cyclophilins Human genes 0.000 claims 1
- 108010068682 Cyclophilins Proteins 0.000 claims 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 claims 1
- 102000018898 GTPase-Activating Proteins Human genes 0.000 claims 1
- 108091006094 GTPase-accelerating proteins Proteins 0.000 claims 1
- 108091006109 GTPases Proteins 0.000 claims 1
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 claims 1
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 claims 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims 1
- 102000004310 Ion Channels Human genes 0.000 claims 1
- 108090000862 Ion Channels Proteins 0.000 claims 1
- 102000005591 NIMA-Interacting Peptidylprolyl Isomerase Human genes 0.000 claims 1
- 108010059419 NIMA-Interacting Peptidylprolyl Isomerase Proteins 0.000 claims 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 claims 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 210000003483 chromatin Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000006916 protein interaction Effects 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 230000004850 protein–protein interaction Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023149774A JP2023161027A (ja) | 2017-04-05 | 2023-09-15 | 協同的結合に関与する化合物及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762481956P | 2017-04-05 | 2017-04-05 | |
| US62/481,956 | 2017-04-05 | ||
| PCT/US2018/025991 WO2018187401A1 (en) | 2017-04-05 | 2018-04-04 | Compounds that participate in cooperative binding and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023149774A Division JP2023161027A (ja) | 2017-04-05 | 2023-09-15 | 協同的結合に関与する化合物及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020513036A JP2020513036A (ja) | 2020-04-30 |
| JP2020513036A5 true JP2020513036A5 (enExample) | 2021-05-13 |
Family
ID=63712657
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504094A Pending JP2020513036A (ja) | 2017-04-05 | 2018-04-04 | 協同的結合に関与する化合物及びその使用 |
| JP2023149774A Pending JP2023161027A (ja) | 2017-04-05 | 2023-09-15 | 協同的結合に関与する化合物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023149774A Pending JP2023161027A (ja) | 2017-04-05 | 2023-09-15 | 協同的結合に関与する化合物及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200199102A1 (enExample) |
| EP (1) | EP3606492A4 (enExample) |
| JP (2) | JP2020513036A (enExample) |
| KR (2) | KR20240033100A (enExample) |
| CN (1) | CN110831632A (enExample) |
| AU (3) | AU2018248417A1 (enExample) |
| CA (1) | CA3058953A1 (enExample) |
| WO (1) | WO2018187401A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9428845B1 (en) | 2010-12-28 | 2016-08-30 | Warp Drive Bio, Inc. | Identifying new therapeutic agents |
| AU2014364589B2 (en) | 2013-12-18 | 2020-02-27 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| WO2016112295A1 (en) | 2015-01-09 | 2016-07-14 | Warp Drive Bio, Inc. | Compounds that participate in cooperative binding and uses thereof |
| TW202413340A (zh) | 2016-07-12 | 2024-04-01 | 美商銳新醫藥公司 | 作為異位shp2抑制劑之2,5-雙取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪 |
| SG11201906209SA (en) | 2017-01-23 | 2019-08-27 | Revolution Medicines Inc | Bicyclic compounds as allosteric shp2 inhibitors |
| CN110785428A (zh) * | 2017-04-05 | 2020-02-11 | 锐新医药公司 | 用于分析蛋白质-蛋白质界面的方法和试剂 |
| EP3678703A1 (en) | 2017-09-07 | 2020-07-15 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| JP2020536881A (ja) | 2017-10-12 | 2020-12-17 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としてのピリジン、ピラジンおよびトリアジン化合物 |
| RU2020123241A (ru) | 2017-12-15 | 2022-01-17 | Революшн Медсинз, Инк. | Полициклические соединения в качестве аллостерических ингибиторов shp2 |
| US11691984B2 (en) | 2018-10-12 | 2023-07-04 | The Scripps Research Institute | Compounds and methods for DCAF-mediated protein degradation |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| AU2020379731A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| CA3159561A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| PE20231207A1 (es) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer |
| PE20240089A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cancer |
| AU2022289610A1 (en) | 2021-06-09 | 2024-01-25 | The Scripps Research Institute | Long-acting dual gip/glp-1 peptide conjugates and methods of use |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN115611989B (zh) * | 2022-10-09 | 2023-08-01 | 武汉理工大学 | 机械活化淀粉衍生物抑制剂的优化制备方法及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2319492A1 (en) * | 1998-02-13 | 1999-08-19 | President And Fellows Of Harvard College | Novel dimerizing agents, their production and use |
| US7220552B1 (en) * | 1999-11-19 | 2007-05-22 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules and their use in the disruption of protein-protein interactions |
| DE10146104A1 (de) * | 2001-09-19 | 2003-04-03 | Bayer Ag | Antibakterielle Markrozyklen |
| AU2004252174A1 (en) * | 2003-06-26 | 2005-01-06 | Migenix Inc. | Compositions of lipopeptide antibiotic derivatives and methods of use thereof |
| US9428845B1 (en) * | 2010-12-28 | 2016-08-30 | Warp Drive Bio, Inc. | Identifying new therapeutic agents |
| WO2012174489A2 (en) * | 2011-06-15 | 2012-12-20 | The Ohio State University | Small molecule composite surfaces as inhibitors of protein-protein interactions |
| TW201629069A (zh) * | 2015-01-09 | 2016-08-16 | 霍普驅動生物科技股份有限公司 | 參與協同結合之化合物及其用途 |
| WO2016112295A1 (en) * | 2015-01-09 | 2016-07-14 | Warp Drive Bio, Inc. | Compounds that participate in cooperative binding and uses thereof |
| EP3355930A4 (en) * | 2015-10-01 | 2019-03-06 | Warp Drive Bio, Inc. | METHOD AND REAGENTS FOR THE ANALYSIS OF PROTEIN-PROTEIN INTERFACES |
-
2018
- 2018-04-04 KR KR1020247006370A patent/KR20240033100A/ko active Pending
- 2018-04-04 WO PCT/US2018/025991 patent/WO2018187401A1/en not_active Ceased
- 2018-04-04 CA CA3058953A patent/CA3058953A1/en active Pending
- 2018-04-04 KR KR1020197032296A patent/KR20200003803A/ko not_active Ceased
- 2018-04-04 CN CN201880037178.XA patent/CN110831632A/zh active Pending
- 2018-04-04 JP JP2020504094A patent/JP2020513036A/ja active Pending
- 2018-04-04 US US16/500,702 patent/US20200199102A1/en not_active Abandoned
- 2018-04-04 EP EP18781380.3A patent/EP3606492A4/en active Pending
- 2018-04-04 AU AU2018248417A patent/AU2018248417A1/en not_active Abandoned
-
2022
- 2022-08-05 AU AU2022211916A patent/AU2022211916A1/en not_active Abandoned
-
2023
- 2023-09-15 JP JP2023149774A patent/JP2023161027A/ja active Pending
-
2024
- 2024-04-10 AU AU2024202332A patent/AU2024202332A1/en active Pending
- 2024-07-29 US US18/787,714 patent/US20250206715A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020513036A5 (enExample) | ||
| US11034672B1 (en) | Tyrosine kinase inhibitor compositions, methods of making and methods of use | |
| JP2022093718A5 (enExample) | ||
| KR20210068473A (ko) | Shp2 활성 억제용 화합물의 제조 방법 | |
| JP5687209B2 (ja) | 第２の抗増殖剤と組み合わせて（−）−ｔｒａｎｓ−３−（５，６−ジヒドロ−４Ｈ−ピロロ［３，２，１−ｉｊ］キノリン−１−イル）−４−（１Ｈ−インドール−３−イル）ピロリジン−２，５−ジオンを含有する組成物 | |
| JP7328323B2 (ja) | ＳＭＡＲＣＡ２／ＢＲＭ ＡＴＰａｓｅ阻害剤としての尿素化合物及び組成物 | |
| JP6896628B2 (ja) | 細菌感染症の治療のための抗微生物性ポリミキシン | |
| SG192464A1 (en) | 5-phenyl-isoxazole-3-carboxamides modulating hsp90 with antitumoral activities | |
| JP2009541474A (ja) | エチオナミド活性の増強効果を有する化合物及びその使用 | |
| Türe et al. | Design, synthesis and molecular modeling studies on novel moxifloxacin derivatives as potential antibacterial and antituberculosis agents | |
| Lal et al. | One-pot synthesis and cytotoxic evaluation of amide-linked 1, 4-disubstituted 1, 2, 3-bistriazoles | |
| JP2016527321A (ja) | 三環式ベンゾキサボロール化合物及びその使用 | |
| JP6515035B2 (ja) | マイコバクテリアに対して活性な抗生物質の活性を増強する飽和窒素及びｎ−アシル化複素環 | |
| WO2016123242A1 (en) | (thio)semicarbazone derivatives and their use for treating cancer | |
| CA3172304A1 (en) | Oxazolidinone compound and methods of use thereof as an antibacterial agent | |
| AU2012257345B2 (en) | Substituted indole derivatives for the treatment of immunological disorders | |
| KR20190010631A (ko) | Ns5a, ns5b 또는 ns3 억제제를 사용하여 b형 간염 바이러스 감염을 치료하는 방법 | |
| WO2013060744A2 (en) | Compounds having an ethr inhibiting activity - use of said compounds as drugs - pharmaceutical composition and product containing said compounds | |
| JP2019519471A (ja) | 環縮合チアゾリノ２−ピリドン類、その製造方法並びに結核の処置及び／又は予防におけるそれらの使用 | |
| Rabbad et al. | Microbes, not humans: exploring the molecular basis of Pseudouridimycin selectivity towards bacterial and not human RNA polymerase | |
| CN111479805B (zh) | 治疗性吲唑 | |
| Chugunova et al. | Synthesis and study of antimicrobial activity of quaternary ammonium benzofuroxan salts | |
| Gobis et al. | Fruzi nski, A | |
| JP2007537212A5 (enExample) | ||
| CN102276593B (zh) | 杂环烯酮腙化合物和制备方法及抗结核菌的应用 |